Co-Diagnostics, Inc.: Form 10-K for the period ended Dec 31, 2017
Filed with the SEC on Mar 28, 2018 and accepted by EDGAR at Mar 28, 2018, 11:52 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2017-12-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Cost of revenue | 12 months2017-01-01 to 2017-12-31 | $302 | us-gaap:CostOfRevenue |
| Gross profit | 12 months2017-01-01 to 2017-12-31 | $7.4k | us-gaap:GrossProfit |
| Research and development | 12 months2017-01-01 to 2017-12-31 | $1.0m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 12 months2017-01-01 to 2017-12-31 | −$4.6m | us-gaap:OperatingIncomeLoss |
| Interest expense | 12 months2017-01-01 to 2017-12-31 | $310.2k | us-gaap:InterestExpense |
| Net income | 12 months2017-01-01 to 2017-12-31 | −$7.0m | us-gaap:NetIncomeLoss |
| Operating cash flow | 12 months2017-01-01 to 2017-12-31 | −$3.2m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 12 months2017-01-01 to 2017-12-31 | $129.3k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2017-12-31 | $3.5m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2017-12-31 | $4.5m | us-gaap:AssetsCurrent |
| Total assets | At period end2017-12-31 | $4.7m | us-gaap:Assets |
| Current liabilities | At period end2017-12-31 | $628.3k | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2017-12-31 | $811.8k | us-gaap:Liabilities |
| Shareholders' equity | At period end2017-12-31 | $3.9m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001477932-18-001468. Last ingested by Listed: Nov 4, 2026, 18:23 ET. Listed shows no prices and gives no investment advice.